UBS lowered the target price for Giant Biogene (02367) to HKD39.5 from HKD79.5 and downgraded the rating to "neutral" from "buy".
The research house said it is turning more cautious about the near-term sales growth outlook and expects Giant Biogene's sales growth to decelerate to 5% during 2026-28.
【香港好去處】2025去邊最好玩?etnet為你提供全港最齊盛事活動,所有資訊盡在掌握!► 即睇

























